Reslizumab | New Drug Approvals
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair Reslizumab Injection
Reslizumab
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
NICE changes mind and backs new drug for severe asthma | Nursing Times
Medication Detail
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab Overview - Creative Biolabs
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers - ScienceDirect
Advisory Committee Briefing Materials: Available for Public Release
Australian Public Assessment Report Reslizumab
Teva files MAA for asthma treatment reslizumab
EU grants marketing authorisation for Teva's asthma drug Cinqaero - Pharmafile
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Dosing and Administration
Clinical Study Protocol Distribution of Eosinophils in Asthma after Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Bli
Israeli Pharma gets FDA Approval for Asthma Antibody
